tetano
Editor, Senior Moderator
- Andreas Puyskens[SUP]1[/SUP]
, Fatimanur Bayram[SUP]1[/SUP] , Akin Sesver[SUP]1[/SUP] , Janine Michel[SUP]1[/SUP] , Eva Krause[SUP]1[/SUP] , Daniel Bourquain[SUP]1[/SUP] , Angela Filomena[SUP]2[/SUP] , Katharina Esser-Nobis[SUP]2[/SUP] , Carla Steffanowski[SUP]2[/SUP] , C Micha Nübling[SUP]3[/SUP] , Heinrich Scheiblauer[SUP]2[/SUP] , Lars Schaade[SUP]1[/SUP] , Andreas Nitsche[SUP]1[/SUP]
Background
There are conflicting reports on the performance of rapid antigen detection tests (RDT) in the detection of the SARS-CoV-2 Omicron (B.1.1.529) variant; however, these tests continue to be used frequently to detect potentially contagious individuals with high viral loads.
Aim
The aim of this study was to investigate comparative detection of the Delta (B.1.617.2) and Omicron variants by using a selection of 20 RDT and a limited panel of pooled combined oro- and nasopharyngeal clinical Delta and Omicron specimens.
Methods
We tested 20 CE-marked RDT for their performance to detect SARS-CoV-2 Delta and Omicron by using a panel of pooled clinical specimens collected in January 2022 in Berlin, Germany.
Results
We observed equivalent detection performance for Delta and Omicron for most RDT, and sensitivity was widely in line with our previous pre-Delta/Omicron evaluation. Some variation for individual RDT was observed either for Delta vs Omicron detection, or when compared with the previous evaluation, which may be explained both by different panel sizes resulting in different data robustness and potential limitation of batch-to-batch consistency. Additional experiments with three RDT using non-pooled routine clinical samples confirmed comparable performance to detect Delta vs Omicron. Overall, RDT that were previously positively evaluated retained good performance also for Delta and Omicron variants.
Conclusion
Our findings suggest that currently available RDT are sufficient for the detection of SARS-CoV-2 Delta and Omicron variants.
https://www.eurosurveillance.org/con...#html_fulltext